I. Introduction
I'liis draft gi~idance document represents the agency-s current thiiilting 011 l ) tlie 171.occss li)r c\!ali~ati~ig the scientific evidence li)r a Iiealtli claim. 2) tlie meanii~g of tlie signiiicant 4cicl1itiiic agreeiiient (SSA) standard in section 403(1.)(3) ol'tlie Federal 1:oocl. Llriig. ;uid C'osiiietic Act (tlie Act) (21 II.S.C7. 343(r)(3)) and 31 ('1-R 101.14(~) . ;111d 3) cr~dihlc scicntilic evidence to support a cli~alified licaltli claim. I'liis guidance document describes the evidence-based review system that I-IIA ititends t o i~s e 10 evaluate tlie publicly available scientitic e\:idencc for SSA licaltli claims 01. cli~aliiied health claims on tlie relatiolishil~ betu.een a si~bstance and a discase or licaltlir.clated conditio~i.' .l'his guidance docuinei~t explains tlie agciic!,'~ current tliinlting 011 the scientific re\~iew nppl~oacli FDA sliould use and is intended to proviile guidance to Iiealtli claim ~~etitioncrs.' ' I I i i gritlance has been prepared by tlie Oftice N~~t~. i t i o n a l I'rod~~cts. Labeling and Dietary Supplenients in I '1)A.s Center for Food Safety and Applied Nutrition I'ol. brevit!. "elisease" \z ill be used as sliortha~id for "disease or health-related condition". "Disease or lie:~llli-related conditioli" is detinecl as damage to an org~ui. part. s t r~~c t~~r c . or s),stem oi'the bod! such th;il it does not ti~nction properly (e.g.. cardiovascula~. disease). or a state ot'liealth Iei~ding to such d\,st'~~nctioning (c.g.. Ii!y7crtension). 2 1 C'FR I 0 I . I4(ai(5) . 3 . l'liis ne\v guidance docume~lL. i f finalized. will replace FDA's guidance (Attaclilllenr 13) "Interim I:\.iclence-bascd Ranking System for Scientific Data" \\;liicli addresses the science revie\+, ol'qualilicd he;rltli claims (littl3::~\v\v\v.ctsa1l.fda.gov -~l~n s i n~~t t f t o c . h t m l ) .
A l~l i o~~g l i tlie i~i t c r i m evidc~ice-based ~.aiil,~ns s! stem giridance i n c l~~d r s a section on ranl;i~ip tlie st~.cngtll o f thc scir~ititic evidence. this tlrat't g~l i t l a l i c~ ~I~CLIIIICII~ cioes 1101 include sucli a section hecause studies arc beins conductctl on the con sum el.'^
Contains Nonbinding Recommendations
Draft---Not for Implementation 'l'lie spccilic topics addressed in this guiclancc document are: ( 1 ) identifying sti~dies tliat cval~late tlie substanceldisease relationship.
( 2 ) identifying surrogate endpoints fi,r clisease 1.is1t.
( 3 ) evaluating tlie human sti~dics to determine \vlietlic~-scientific co~icli~sions call be drawn tiom them about the substnnccldisease relationship. ( 4 ) assessing tlie metliodological cluality ot'cacli human sti~cly fro111 \vliicIi scientific conclusio~is about ~l i c substnnccldisease relationship can be dra\+:n. nntl ( 5 ) cvali~ating the totality ofscientilic c\!idcnce.
1'1)/1'5 guidance documents. including this guidance. do not establish legall! cnforceal,le rc\l~c~isih~Iitics. Instead. guidanccs describc the agencjr's current tliinlting on a topic and \liould he \liewed only as ~.ecommendatio~is. ilnless spccitic regulatory or \tatutnrj ~.ccli~irements are cited. The LISC of the \+orci .\liol~ld in tlie agencjr's guidances means tliat sometliing is suggested or recommended. but not required.
'l'hc Ni~trition 1-abeling and Education Act ol' 1 C)C)O (NLEi1) (Pub. 1~>. 101 -553) \\,as clcsigncd to gi\,e consumers more scientifically valid infor~iiatio~i bout li~otls they cat. Among otlier pro\..isions, the NLEA directed FDA to issue regulations providing li,r tlic LISC oi'statements tliat describe tlie rclationsliip between a substance and a disease ("licaltli claims") in the labeli~ig of foods. including dietary supplements. altct-sucli s~utc~iients liave been revie\ved and autliorized by I-'I)A.~ For tlicsc liealtli clai~iis. that is. slatements about suhsta~iceldisease ~.elationsliips. 12DA has delined tlie term "substance" by regulation as a specific food or food component (1 1 C'FR 101.14(a) (2)). An ~ti~tliorized liealtli claim may be i~sed on botli conventional foods and dietary supl'lcments. pro\,ided tliat the substance in tlie ~'roduct and tlic product itsclt'meet the appropriate standards in tlie authorizing regulation. Health claims arc directeci to tlie general p o p~l a t i o n or designated subgrc,ups (e.g.. the elderly) and are intclided to assist I lie consumer in mai~itaining Iiealthfi~l dietary practices.
In cvaluati~ig a petition for an authorized healtli claim. FDA considers whether the c\,iclence supporting the relationship that is tlic subject ol'tlie claim meets tlic SSA standard. l'liis standard derives fiom 21 I~J.S.C'. 343 (I.)(; j(H)(i). \vIiicIi p~-o\,ides tliat FDA shall authorize a Iiealtli claim to he i~scd 011 con\~e~itio~ial l i~o d s if tlic agency "determines bascd o n tlie totality of tlic 1)~1bIicIy ;~\.;~ilablc c\:idencc. (incli~ding evidence li-om \+-elldcsiyied studies conducted in n manlier \\~liicli is consiste~it Ivitli generally rccognizcd ~l~i t l c r s t a n~l i~~g o f various 1x)ssihle ranking systems tllat could he u\cd t o describe 11ic strengrli ol'tlic c\/itlcnce ti^ a he:~ltli claim. F D A iritrnds to ~.ees;l~iiine its ranking s y i l e~l i s ant1 issue app~.opriate ~~~i t l a~i c c once these studies arc completed. I n addition. il-this guidance is tinallzctl. it \vill r-ul>lace "(;uidancc ti)^-I r l d~~h l r ! : Significant Scientific Agree~nent i n tlie I<evic.\v o f I lealtli C'l;lilns f'or C'onvenrion;~l IToocls and I)iet;ll-!~ S~il>plt.rncnts." I 111 1007. C'ongrcss enactecl r l l r Food and llr-ug Adnli~iistr-ation Mniler-~lizatio~i Act. \vlllcll esrablishetl an :rltrl'native a~~t h o r i z a t i o~l procedur-c fcir Ilealtli c l a i~i i s based or1 a~~r h o r i t a t i v e statements o f certain federal c i c n t i t i c bodies o r {lie National Acndc~ll!; ot'Scicnces. I'llis guiilance doculllent does not ;lilcIress thar ;~ltc~-n;lli\'e p~.ocedurr.
Draft---Not for Implementation scic~ititic procedures and l~rinciplcs). tliat there is signiticant scientific agreement among experts qualified by scientific training ;uid experience to evali~ate such claims. tliat the claim is suppo~.ted by sucli evidence." 1-liis scientific standard was ~>rescrihed hy statute li)l-conventional h o d liealth claims; by regulation. FDA adopted tlie same standard ti)r clictary sul~l~lements health claims. See 2 1 ('FR 1 0 1 .14(c).
'I'lic genesis of clualified liealtli claims \+-as the cnil1.t of appeals decision in l ' c r l l . .~o l l 1.. / / I ( ' c~~~o~~) . 111 that case. the plaintiffs cliallc~igecl FDA's decision not to ai~tliorize Iicall.li claims for four specific substance-disease relationships in tlie labeling ol'dietary si~l'plcnic~its. ,AltliougIi tlie district court ruled li)r I;L)A ( 1 4 1:. S L I~~. 2d 10 (11.11.C'. 1008). tlie I!.S. C'oi~rt of.4ppeals for tlic L1.C' . ('il.cuit re\:erscd tlic lo\+!cr coiirt's decision ( I04 I:.3d 650 (L1.C'. C'ir. 10c)O)). The appeals coi~rt held tliat tlic 1:irst Amendment docs no1 permit IYDA to reject Iicaltli clainis that the agencjr dete~.mi~ics to he potentiall! misleading i~nless the agent!' also rcasonahly determines tliat a disclaimer \voi~ld ~ior eliminate the potential deception. 'I'he appeals court also Iield tliat the ildministrativt. 1'1-occdure Act (APA) reclirirecl FDA to clarify the "significant scientific ;lgreemcntM ( S S A ) standard fi)r authorizing Iicaltli claims. .phis glridance document \\.as issued to clari t.y FDA's interpretation oi'the SSA sta~itiartl in response to tlie court oI'al>peals7 sccond holding in l'crrr.~ol~.
( ) n 1)ecember 20. 2002. tlie agency announced its intention to extend its approacli to iml~lementing tlie P~L /~. Y O I I decision to include Iieal~li claims lhr con\lentional thods ((37 I*'ed. Reg. 78002). Recognizing the need for a scientific fra~iie\l;o~.k for cli~alified licaltli claims. the 'l'aslc Force on "('onsumer Health Intijrmation fbr Better Nutrilion" \has li)r~iiecl. 'l'lic .l'asli Forcc recognized that tlierc could be significant pi~blic health benclits \ \ lie11 consi1111e1-s liave ;~cccss to. and use. Iiiore and better infbrmation in con\.cntional Ii)ocl as \cell as dietary supplement laheling to aid them in tlicir 1~i1rcIiascs. i~ilhrmatio~i tliat goes hcyond j i~s t price. con\!eniclice. and taste. hut extends to include science-hascd Iicaltli f'nctors. Armed \\;it11 more scientificall!. based i11ii)rmation about the lilcel! Iicaltli bcnclits of tlic liwds and dietary supplements the!, ~~urcliase. consumers can malic a ranpihle difference in their ow11 long-term liealtli by lowering their risk 01' ~i i~l~i e r o i~s clironic diseases. ' 1. 0 maximize tlie ~i~b l i c liealtli bcnefit of FDA's claims re\.ie\v 1>rocess, the I'ask Force's I.'inal Report? pro\:ides a procedure to prioritize on a case-hy-case basis all complete petitions according to se\.eral factors. including wlietlicr the l'oocl or ciie~ary supplement that is tlic subject of tlie pctition is liltely to Iia\:e a significant impact on a scl.ious or lilk-tli1.ct1tcning ill~iess; the strength of'the e\:idencc: ~:lietlier consumer reseal-cli lins hccn '' See ~~~i~l~~l l c e (Attachment E ) entitled "Interim 1'1-oceclul.e Ibl-(Jl~alitied Iiealtli Clainls." . l~~l y 10, 7003 (I11tp: '.\v\\,\v.cban.fda.gov. -cl1iis/liclmg~1i3.litml)
Draft---Not for lrn~lernentation ~~o \ : i d e d to sho\v the claim is not misleading; \vl~etlie~. the substance o f the claim has i111dergone an FDA safety re\:iew (i.e.. is an ui~tliorized food additive. has heen C;cner:~lly Ilccognized as Safe (GRAS) aftirmed. listed. or has recei\.cd a letter of "no ohjcction" lo a (iRAS notification): whetl~er llic substance tlint is tlie subject ol'the claim has hcen ;~decluatel!. cl~aracterized so that the rele\zance ot':1vailn17le stildies can he evaluated:
\\.lictl~er the disease is defined and evaluated in accol-dance \vith genesall!, :~cccpted criteria established b!. a recognized bod!' of qilaliticd experts: and ~: l i c t l~e r rhere is prior sevie\\ of tlie evidence or the claim hy u recognized body ol'clualificd experts. As 1>;1rt ol'the -Task 1;ol.ce's final report". FDA de\!eloped an interim evidence-based ~.e\.,ie\v s>stem tliat the asency intended to use to e\.nli~ate the suhstanccldisease ~~el:~tionsIiips that are subjects of qualified I~ealtli claims. In reviewing lhc Ilecemher 32. 1000 SSA guidance document and the 3003 Tasli FOI-ce repol't, it becanle apparent to tlie agcnc). tliat the components of the scientific re\'iew process for an SSA health claim and qi~alificd health claim are very similar. Because oi'the similarity hetween the scientific ~.cvie\vs 1i)r SSA and clualitied health claims. Is'IIA intends to use the approach set out in I.liis yi~idance for c\~~iluating the scientific evidence in petitions that are submitted li,s an SSA 11ealtIi claini or clualilicd liealtli claim. ' [ h c e\,idence-based revie\+, system set o i~t i l l tliis guidallce \vill assist tile agencj. in determining wl~ether the scientilic evidence mec1.s rlic SSA standard or. il'not. \\:l~etlier the e\.idcnce supports a qualiiiecl hcaltl~ claim. In ~~dclition to a science revie\$. health claims undergo a regulator!, review. 1 Ie;~lth claims 1.1iat meet tlie SSA standard are aut11orizt.d hy l,~~hlical.ion of a tinal I-i~lc or an intcsim linal 1.11le in the 17eilerul Register. For cli~aliiicd Ilealth claims supported b!, credible widence. I. ' I)!\ issues a Icttcr regarding its intent to consider enforcement discsetion.
I l l . Evidence-Based Review System for the Scientific E\~aluation of Health Claims

A, What is iln Evidence-Based Review System'?
:\n evidence-based revic\v s y t e m is a systematic science-basecl evaluation of the strcngtll ot'the evidence to S L I~~O I -t a statement. In the case ol'health claims. it e\;aluates the .srrcngtIi of the scie~~tific evidence to support a 131-oposed claim about a substancelcliscasc ~.clationsIiil~. The evaluation process involves a series of steps to assess scientific stuclics ;rnci other data, eliminate those from wIiic11 110 COIICIUS~~IIS about tlie substanccldisease elationsh ship can be drawn. rate the renlail~ing studies for n~etliodological cluality and cvaluate tlie strength of the totality of scientific e\,idence hy considering stitdy ty17cs. ~nctliodological quality. cli1;111tity ol'e\-idence 1i)r and against the clai111 (taliing into ; I C C O L I I I~ tlle numbers of \~arious t~~p e s of studies and study sample sizes). relt.\!;~~lce to the I ..S. po17i1lation or target subgroul). rep1 ication of study results s~rpporting t l~c l~roposed cl;1i111. and overall consistency of the e\.idcnce. Alter :lssessing the totalit! ot'the scicntilic evidence. FDA determines whether t1ic1.e is SSA to support an a~~tllorizcci 11ealth claini. or credible evidcnce to suppc~rt a qilalificd hcaltl~ claim. 
Contains Nonbinding Recommendations
Draft---Not for Implementation 13. Itlentifj,ing Studies That Eviiluate the Substance/Disease lieliitionship 'I'lic agency considers the publicly a\jailal3le data and ~. r i t t e n information pertaining to the r.clationship between a substance and disease. Before the strength ol'the e\,idencc for substunce/discase I-elationship can be assessed. FDA separates indi\'idual relc\:ant articles (111 hitman studies ti-om other t!yes of data and inih~mation. FDA intends to lhcus its ~.c\,iei\ primarily on articles reporting human inter\~cntion ;uid ohscr\~ational stildics hecai~se only such stitdies can provide evidence I'ro~ii wliicli scientitic conclusions call be cIl.:tri:n a b o~~t tlie suhstance/dise;tse rclationsliil, in humans. Nest. the agcnc!, considers :I ni~mbcr ol'tlircsliolcl cli~estions in the revie~i: ot'tlic scientific c\.idencc: Sti~dics should identify a substance that is rneasu~.ahle. .iI"s~thstance" is ddined as a slxxilic Ihod 01. component of h o d regardless of \vlictlier the li)od is in con\lcntional liwd li)r~ii or a dietary supplement. 2 1 ('FR 10 1 .14(a) (2 (2)). If tlie suhstancc is to be consumeel at other than decreased dietar! Ie\:els.
S lie substance milst contribute taste. aroma. 11i1triti1:e value. or :I technical cffkct listecl in 21 C'I:I? 1 7 0 . 3 ( 0 ) to tlie fond. and must be safc and law-till Ihr use at tlie le\.els ncccssur!.
to .j i~sti t:\. a claim (2 1 C'1;R 1 0 1 .14(b)(3)). "Disease or health-related condition" is defilied :LS clamage to an organ. part. str~tcti11.e. 01. sj.stem of tlie bod). such that it docs not I'i~nction 1p1'01~crl!~ (c.g.. cardiorlasci~lar disease). or a state ot'liealtli leading to such dysfirt~ctioning (ct.2.. 1ij.pertension). 2 1 ('FR 1 0 1 . 1 4 ( a ) ( 5 ) . Stildies s l i~i~l d idelitif). a me;tsurablc disease or health-1.elatc.d condition b! , either measuring incidence. associated ~iiortalit!.. or \.alidated surrogate endpoi~~tstliat predict risk ol';t slxxific disease. ,2l'te1 considering these tlireshold issues. 17DA categori7es tlie stitdies by t ! pe
Intervention Stitdies
In all intervention study. suljects are 13rovided the suhstancc (food nl-fi>od component) ol' interest (intervention groirp). t!lpically either in the form o f a con\rcntional food 01. clietar!. supplement. .l'lie quality and cluantity of the substance sliould be controlled li>l.. In ~.anclomizcd controlled trials. s u~j c c t s are assigned to an intervention g r o i~p hy cliancct ~.i~tlic~. than systematic all!^. Indir,idual sub.iccts ma!. not be siniilar to each other. hut the Sce 7 1 [~J.S.C. 3 2 I(f'fj( I ). "Nutritive value" is defined in 2 1 C'FR 10 1.14(a)(i) as value ill sustainilig human esistc~ace ( 3~ sucli ~~-o c c s s " e sas 13romoting gro\vtIi. replacing loss oi'cssential nlltrients. 01- providing energ!
Contains Nonbinding Recommendations
Draft---Not for Implementation intcr\:eiition and control groups sliould be similar al'ter randoiiiization. Randomized controlled trials ol't'er the hest assessment ol'a causal relationship bet\i.c.cn suhstancc ~uid ;I disease because the!. control ibr kno~vii confounders of res~rlts (i.c.. otlicr k1ctol.s that coilld affect risk of cliseasc). 'l'lirougli random assignment of sul?jccts to the inter\:ciitiori and control groups. these studies avoid selection bias --l.liat is. 1.11~ possibility that tliosc sul?jects niost lilicl!-to have a Iil\:orable O L I~C O I I I C . i l i d c~~c~i d c~i~ oI';11i intcr\~e~itioii. are ~,refercntially selected to rccei\,c the iiiter\,cntion. I'otcntial bias is also ~.edilced by "blinding" tlic study so t h i~t the sul?jects clo not lino~v \vlietlici. lliej. :Ire l-ecci\!ing the ilitervention. or "double blinding," in ~~I i i c l i neither ~Iie sul?jccts 110s tllc ~.cscarclier u;lio assesses the outconie lino\vs \\:lie is in tlie intcr\,ciition groi112 ;111d \\:lie is ill the colitrol g1.0111). [3y controlling tlie test en\.-iroiiiiient. incl~~diiig tlie aiiioi~iit and comlx)sition ol'sitbstancc co~isumed and all ntlicr dietary factors. these studies also call 0 mini~iiizc tlie efi'ects ol'\~;rrinbles or con1i)unders 011 tlie results. T1iereti)re. randomized. contl.olled intcr\,ciition studies pro\:ide tlie strongest evidence of u:lictlie~. or lint there is a rclationsliil, between a si~bstancc and a disease ((;reel-et al., 2000) . I.i~rtIiermore. sucli studies can pro\iide convincing evidence of a cause and el'lkct ~.elario~isIiip bet~vcen an intcrventio~i and an outcome (I<racmer et al.. 2005 at 1 I3 1. I<andomizatio~i, liowe\'er. ma!; resull in uneqi~al distribi~tion ol'tlie characteristic ol'tlic sul3.jccts bet\.veeii tlie control and treatment groups (e.g.. baselilie age or hlood I scrilm 01. ~pl:~sma] LDL cholesterol levels are significantly difkrent). Iftlie baseline \ d u e s ul-c signilicntitly diiyerent. tlicn it is difficult to determine il'difi'erenccs n~ tlie end ol'tlie stildy \\:ere clue to tlie intel.\.;cntion or to differences a1 tlie beginning ol'tlic stitdy. Wlic~i 1l1c substance is pro\;idcd as a supplement. n placeho sliould he 171-ovided to ~l i c control gt.oi~p. Wlleli tlie substance is o tbod. it may not be possible to ~~r o v i d e ;I l~l;~ccho and rlici-efi3rc si~l?jects in such 21 study ilia!. not be blinded. Altliougli tlie stildy may not 13c hli~ided in this case. ;I control group is still necdcd to dra\v conclusions 1.1-0111 tlic sti~cl!..
I<anclomized controlled trials typically have either a 13al.allel or cross-over design. I':~r:~llcl design sti~dies in\!olve two g~-0111~ ol'si~hjects. the test group 2uid tlic control ~I . O L I~~. \.\:liicIi siiiiultaneousl!~ receive tlie substance or sen7e as the control. respectivcll.. ('ross-o\:cl design involves all sul!iects crossing o \ w linm tlie i~itcr\,entio~i groi~p to tlic control group and vice \.crs;~. after a detincd time period.
:2Itll0~1gIi inter\icntio~i studies are tlic most reliable catcgor!: ol'studies fi>r determining ;I cause-ancl elfect rclationsliip. generalizing liom the sri~dies conducted on selected ~x ) p~~I ;~t i o~i s to different 1w1~~1lati01is may not be sci~'~ititicalIy v;~Iid. For esamplc. if tlic e\-itle~icc consists of'studics showing 2111 associ;~tion between intake oi'a suhstancc anci rC~ii~ccd risk ol'.ju\:enilc diabetes. then sucli sti~dies sliould not hc cstrapolared to the risk ol'diabetcs in adults.
()l>ser\ ationnl Studies CJ C'onli)~tnders arc fr~ctol's associated wit11 both the discnse in cl~lcstion ancl tlic interven~ion. and LliaL il'not conL~-olletl Ibr prevent all investiyator ti-0111 heilly able to co~lclude tlia~ an outcome \\)as caused h' a n ililcrvention.
Draft---Not for Implementation Ohscr\tational studies measure associations bct\\;ceii the s~~b s t a n c c and disease.
Obser\~ationnl sti~dies lack the controlled setting ol'inter\;cntion studies. Observational !;tildies are most reflective of' free-li\lingl" populations and rliay be ahle to cstahlisli an ;lssociation between tlie substance and the disease. In contrast to intervention studies. obser\:ational studies cannot determine whether an obscr\;ed relationshil> I-cpresents u rclationsliil7 in \vIiich tlie substance caused a red~lctioli in disease risk 01. is a coincidence (Seliipos et al.. lc)c)9). Because tlie sub,jccts arc not randomized hascd on \:ario~~s disease t-isli filetors at tlie beginning of the study, I~IIO\V~I co1ifoundc1-s o f disease risk need to be collected and ad,iusted Ibr to minimize hias. For example. inforniation on each sul$cctts ~.isli l'actors. such as age. race. body weight and smoliiiig. sl~oulcl he collected and used to adji~st tlie data so that tlie substanceldiseasc rclationsliip is accurately tiic:~surcd. I<isIi Iictors tliat need to he acijilstcd for arc dcter~iiined I~Icacli disease hein? studied. ];or csamplc. rhe rislc of cardio\:ascular clise~rse increases \\;it11 age. tliercli~re an acljust~iicnr li)r age is needed in order to elimin~rte ~>oteiitial confounding. 111 tletermining \vlictlier a suhstancc tliat is the sul,ject of the claim Iias been ~iieasurcd apl~opriately. it is important to critically evaluate tlie mctliod oi'assessmcnt of dietary ilitalie. Man!. observational studies re]! o n selt-reports ol'dict (e.g.. diet rcco~.ds. 24-Iioilr I-ccalls. dict histories. and food frecluency cluestionnaircs). \cliich are estimates o1'li)od i~ltal\c (National Kcscal.cli Council. 1080) . Ilict records are based on t l~c premise tliar li)od \\ciglits 17rovidc an :lccurate estinlation ol'ibod intake. Sul!iects \veigli tlie foods rllc! consu~iic and record those \:slues. 'l'lie 24-lioul recall mctliod recli~ires tliat s~~l!jccls tlescribc \~:liicli foods and lie\\ much ol'cacli food the) consumed during the prior 24-IIOLII. pel-iod. Diet liistories ilsc cluestionnaircs or inter\:ie\\.ers to cstimatc tlic t!,pical dict ol'sul?iects o\ cr a certain 17criod of tinle. i \ t i~d fi.eclucnc!. clucstionnaire is the most corntiion dietary assessmelit tool iiscd in large obser\~atioiial stilelies of diet and Iicaltli. Validated foocl fi-equcncj* cluestionnaires are more liable in estiiiiatil~g "itsual" intalic of' li)ods compared to diet records or 24-liour recall metliods (Subar et 31.. 200 1 ). 'l'lic ~~~~~~~~~~~~~~e aslis participants to report the tiecluenc!~ ol'coiisuiiiptioii and portion size l't.0111 a list o f l i~d s over a defined period of tiliic. One problem \\-it11 tlie dietar!, intake ;lsscss~iicnt methods described above is that 111c1.c may he bills in the s e l l -r e p o r t 01' cerrai~i li)ods. I-or example. individuals \vlio are o\;et.\veigIit tend to under-~.cporr rlicil-1701-rion sizes (1:legal ct ill.. 1000) and t1iercli)rc the ;lctual aliiou~it of si~hst:rliccs I I consi~med is oi'te~i i~nderestimated. I I' rlicre arc reliable biomarliers ol' ititalic ol'a suhsr~uicc. these hioli~arliers arc oi'tcn nieasured ratlirl than using sel I-reported i~italics.
()bsc~.\,ational studies ma!, bc p~.ospectivc 01. retrospecti\ic. In prospective studies. i~i\~cstignto~.s 1.ccruit sub.jccts and observe tliem prior to the occuri-ciicc ol'tlie disease oi~tcoiiie. I'rosl7cctive ohser\!ational studies coiiil,ai.c the incidence ol'a disease wit11 exposure to rhe substance. I11 retrospective studies. i~i\'cstigatoi-s review tlic niedical I t 1 I-l.ce-livirlg ~~o l~u l a t i o~l s l-el>rc.sellt those \vllo consume diets and llave lil'est! Ics (e.:.. slllol<ing. c I~-i~l l i i~l g . ;111(l csercise) o f their own choice.
1 1 13iolnnrl<c1-s of intnlte are IneasuI.elllelit?; of the suhsta~ice itseli'ol. a nletabolite of tlle sul)stn~lcc In I~~o l o g i c a l sarlll>le\ (c.g.. ser-~lrll s e l r l i i~~l l l ) tliat Ilave bee11 validated to c o l i t i r~l l that they ~.cilt'ct the illtake o f r l l i~t s~~b s l n l l c c .
Draft---N o t for I m p l e m e n t a t i o n ~.ccords of subjects andlor inter\!iew subjects after the disease lias occurred. I<ct~-osl,ecti\~e s t~~d i e s are partic~rlarly \'ulner;lble to measurement error and recall hias h e c a~~s c the!. rely on s~~tl.jects' I-ecollections of'\vliat they co~isumed in tlie past. l3cca~1se
ol'tlie I imited ability of obser\!ational studies to control for \~ariahles. they are olten s~~sceptihle to c o~i t b~~n d e r s . such as complcs substanceidisease i~iteractions.
lVcll-designed obser\~ational s t~~d i e s can pro\.idc nselhl i~ilbl-]nation 1;)s identilying ~x'ssiiblc associations to he tested hy inte~wntion studics. hut tlic!; cannot ~p~'o\;idc co~i\~incing c\'idcnce of cause and effect (KI-~remer ct al.. 2005 at 107) . 111 contrast to inter\.ention studies, e\.;cn tlie best-designed obsc~.\.:rtional studies cannot establish cause and ci't'ect hct\+:cen an inter\:ention and an outcome (l<raemcr et al. 3005 at I 14) . I lo\\;c\ze~-. as discusscci abo\!e. inter\~ention studics can test \\:lietlicr tliere is c\ricience to slio\\: 21 cause and effect l~ct\\:eeii a substance and a reduced risli of'a disease. Ohser\:~~tional studics from \?;liich scientific conclusio~is can be drawn. in some situatio~is. can he suppurt for ;I s~~hstanceldiseasc relationshi17 l'or a n SSA or clualitied health claim. I:acli obser\.ational study design lias its strength alid \?;ealinesscs as discussed helo\v (Sc~iilx'sct al.. I OOe)).
( 'olror/ .s/z~~lic~.v are prospective studies that compare tlie incidence of' a disease in sul!jects \?;hr' receive a specilic exposure of i.hc substance that is tlie sub.ject oftlie claim \?;it11 tlic oLltcomc of sul7.jects \vho do not receive that csposure. Because the intalic oftlie sulwtancc precedes disease de\!elopment. this study clesign ensures that the subjects al-c not consuming the s~tbstance in response to having tlic disease. C'oliort studics can yicicl I-clativc csti~iiates ol'risl< ( S~l i l o and Nieto. 1000)." C'o1iol.t studics are considered to be tlic ~iiost reliable obsel-\,ational study design ((ireel-el al.. 2000) .
In L . ( I , S C J -C .~~~/ I '~/ .s/z~~lic~.s, s~~l?.jects \\.ith ; I disease (cases) are compa~.ed to s~ll7.iects \vlio clo not Iiave tlic disease (controls)." Prior intake of rhc substance is estimated fiom dietar!: asscssmcnt methods for botli cascs and control. 'These retrosl7ccti\:e studies olicn asli about ti,ocl consuniption at least I year prior to diagnosis oftlic disease. making it dil'ficult to obtain an accurate estimate of intake. I:urtliermo~.e. a licy ~~s s u r n~~t i o i i is tli:~t li,od consu~iiption has not bee11 alterccl hy the disease process or hy kno\vlcdge ol'Ii;~\..ing tlic cliseasc. Tliirs. the case-control study design docs not control ii)r changes in int~~lic C ; I L I S C~ hy or in response to tlie disease. Case-control studies can yield an odds satio 14 \\.liicli is an estimate ot'tlie relative I-is]\: of getting tlic disease (Szlilo and Nieto. 3000). (lase-control sti~dics are considered to he less reliable than cohort s t~~d i c s ((ireel. ct al.. 2000) . 12 I<ela(ive risk is espressed as the ratio o f the risk (disease incidence) in exposed individuals to tliar in ~~nesposecl individuals. I t is calculated ill prospective cohorts by lneasuring exposure oi'the substance in sul,iccls \\,it11 arid \s'itliout tlisease. A n ;~d,j~~sted relative risl; controls for potential confoundel.\. I ' A l l cszrmple ot'a case-control study is a sludy clesign that assesses ~,aramt.ters related to the freilue~ic!~ z~nd i l i s t r i h~~t i o n o f tlisense in a ~p o p~~l a t i o n . such as leading causc ot'death.
' I A n odds lxtio is the odds ot'de\lelopiny tlie disease in cspost.ci compared to ~~nesl,osecl intlivitluals. It is c;~lculated 111 case control st~~clies l>y l i l e a s~~r i~i g disease development ill s~~L!jccts hased on csl,osi~~.c t o ~l i c \~~h \ t a l i c e .
Adiusted odds ratio controls for potential c o~l t i )~~~i d e~. s . sti~dy uses sl~l>.iects li-om : I prc-delincd cohort. sucli as tlie popi~lation ol'aii ongoing coliort st~~d!.. C'ases arc sul!jects diagnosed \\.it11 tlie clise:isc (e.g.. lung cancer) in the coliort. In a nested-case control stud!.. controls are sill?jects selected from individuals at rid\: each time a case (e.g.. lung cancer) is diagnosed. In a case-cohort study. co11t1-ols a1.e selected randomly from tlie bascl ine coliort. (Szklo and Nieto. 2000 PA(iE 34) . Either a I-elati\re risk 01. odds ratio ma!; he calc~llated in rliese types of studies. Nested-case control or case-cohort studies arc co~lsidered lcss reliable than coliort studies but more reliable tlian case-control s t~~d i c s . Ilal>orts tliat discuss a number ot'different stildics. such as review articles. do not ~~. o \ ; i d e sufficient information on tlie indi\~idual sti~dics re\~ie\vcd tt)r FDtZ to determine critical ele~nents s~rcli as tlie study popi~lation characteristics and tlie composition ol'tlie products used. Similarl!.. tlie lack ol'detailcd infi~rmation on studies summarizccl in rc\~ic.\\ articles prevents I-'D;2 from determining n.Iiethcr tlie stildies arc Ila\ved in critical dements silcli as desigli. c o n d~~c t of studies. and data analysis. I;DA milst l~e ahlc to ~.c\.ie\\: the critical elements of a stndy to determine wlietliel-an! scientific concll~sions call bc d~.a\vn i~'1.0111 it. Therefore. FDA intends to i~s c ~.c\.ie\v articles and similar 15 In :I fe\r c~mss-sectio~ial st~ldics. it is a ti~~ie-wries s t~~d > , tliat coliiparcs o~~t c o~i i e s d u r i l i~ dilli'rclit time pcl.iods ( c .~. . \r,lietlit.r tlie rate o f occurl'elice ol'a pal.ticulaloutcollie during olic tive-?,cal. pel.iod clialigetl c1111.iliy a aubseclue~it five-!,ear period). 1 G Kc\ ic\r il~.ticI~'\ s~llnmarize tlie tilldings of individual srudies. p~rhlic;~tions to identify reports of additional stlldies tliat may be ~~s c f i~l to thc health clairii I-cview and as background about tlie substanceidiseast: reIationshil>. lt'additional st~rdics arc identified. the agency intends to evaluate them indi\;id~lally. Most mcta-I Y an;~l!,ses. ' because they lack detailed information on the studies sumlnasized. will nnl!, he used to identify reports of additional studies tliat may he ~rsetirl to tlic Iiealtli claim ~-e\.ic\\; arid 11s bacliground al7o~1t tlie substa~ice-disease 1.clationshil7. FDA. Iio\\,c\.c~.. illtends to consider as 17;irt 01' its licaltli claim rc\:ie\v process a riicta-anal!.sis tliat rc\:ic\z:s all (he puhlicl!, a\.uiIal.>le studies 011 tlie substanceldiseasc rcIationshi17. .l'lic I-c\ ic\\cd sti~dics should be consisterit \s.itli tlie critical t'leriients ancl cluality and otlicr li~ctors set O L I L it1 ~Iiis g~~i d a n c c ;111d tlie appropriate statistical ;~lialyses aclccluutcl!. coriductcti.
Aliimal and i l l ~~i / r , o Studies IZI)A intends to use animal and it7 i)i/~-o stildies as bacl<gro~lnd information I-cgasding riieclianisms tliat might be involved in a n y relationship between tlie substance and tliscasc. l'lie 17Iiysic)logy ol'animals is dil'ferent than tliat ol'lium~ins. 1 1 7 \.i/r.o studies ;ISC cx)nd~lctcd in an artificial en\;ironmt.nt and cannot account l i~r a multit~rde ol'norm;~l pIi!:siologicaI processes s~~c l i as digestion. absorption. distribution. and riictaholism tliat al'lLct Iiow humans respond to [lie co~isumlltion ot'foods and dietary substances (IOM. 2005). Animal and iri ~'i/r.o studies can be ilscd to generate liypotliescs or to csplo~.c a riicclia~iis~i~ ofaction of ;I sl7ccitic food cornpollent tlirougl~ controlled animal diets. hut do riot pro\:ide information from \vliich scientilic conclusions can be drawl1 regarding a rcl:ttionsliip between the substance and disease in Iii~mans.
<'. Identifying Surrogate Endpoints of Disease Risk
I '1
Susrogate endpoints are I-isli biomarkcrs that have been s l i o \~n to he valicl 171xxiicto1.s ol' tliseasc r.isl< and therefore 1i1;1y be used in place ol'cliriical mcas~~rements ol'tlic incidclicc ol'tlic disease (e.g.. diagnosis ol'disease) (Spill<cr ct al. 1001 ). I3ecause ;I nunihcr ol' tliseascs develop a long period of time. it ma\; not be l>ossible to carry out tlic slud! Ii)r a long enough period to see a statistically meaningfill diffesence in tlie incidence 01' iliscase among study subjects in the trcatnlent and control g r o~1 1~. ' ' I Itisli hiomar-l;ers are biological ir1dicato1.s tliat signal a cliangcd plrysiological state t l i i~t is associalccl \\,it11 the risl, ol'a cliwase.
Contains Nonbinding Recommendations
Draft---Not for Implementation 'l'hcre can be rn~~ltiple patInva!:s to a specific disease. such as cardiovasci~lal disease. 'l'I1ercli)re. the accepted surrogate endpoints tliat arc involved in a single l,ath\\~:ty nia!, no1 he ;tlq?licable to certain s~tbstanccs that arc invol\,ccl in a different patli\i.a!~. I:ol csaml7le. the long chain omega-3 I'att? acids generally lia\e no effect o n serum I.l>I-. cliolesterol Ic\:els and s t~~d i e s suggest tliat these fatt!? acids alter c:rrdiovasci~lar risk tllro~~gli ;I cliI'Ii.~-el~t 1~1tIi~;a.;. Tliereli)~.e. LDL cholestcl-ol levels cannot be ~~s e d in crral~~ating tlie I-elationsliil, het~veen tlie long chain omega-3 fatty acids and risk of CL?~~~OV;ISCLII~II.
tliscase.
I). Evaluating Human Studies
Illides [lie e\,idence-based review approach set out in this guidance. FDA intends to c \ . :~l~~a t e each individual lii~man stud). to determine u.hether any scientilic concl~lsions a b o~~t the suhstanceidisease relatio~iship can be drawn liom the study. Certain critical elements of a study. such as design. data collection. and data a~ialysis. 111ay he so s e r i o~~s l y fla\+:ecl tli;lt the!; make it impossible to draw. scientific conclusions from rhc sri~d!:. 1:lli'l does not intend to use studies from which it cannot clra~: :IIIJ. s c i e~~t i j i c conclusions about tlie substanceidisease relationshil,. and plans to clin~inate such s t~~d i c s lium I~~~. t h e r revic\v.
Uelo\is are examples of questiotis that the agent!: intends to consider lo determine \vlletlier scientific concl~lsions can be drawn t'rom an interventio~i or ohscrvation~rl study about tlie substanccldiseasc rclationsliil,. Iia\:e tlic disease tliat is the subject of'tlie claim. FDA considers e\,idencc li.om st~ldies \ \ irh sul?jects \+:l~o Iiave tlie disease i.Iiat is the sul?ject o f t h e claims only if it is scientifically appropriate to csti-apolate to individ~~als \vho d o not have tlie disease. l'liat is. rlie available scientific evidence demonstrates tliat ( l ) tlie mecI~anism(s) for tlic mitigation or treatment ef'fects measured in the diseased pop~~lations are the same us the ~iieclianism(s) for risk reduction effects in non-diseased pol~i~l;ltio~is and (2) tlie subst:i~ice aI'l>cts these meclinnisms in the same m:ay in both diseased and healthy ~>eoplc. If'sucli e\,idence is not available. the agenc! cannot draw any scientitic concl~tsions from studies rhat used sul?jects that h a \~e the disease tliat is sul?jcct of l.he Iie~~lth claim to evaluate tlic substanceidisease relationship ;itid. therclbre. the agency does not inrend to use these sri~dies to e\.aluate tlie substance/disease rclatioliship. On the other hand. i I : tor csample. .opriate co~itrol LJI.OLI~ represents study sul?jects who did not rccci~ie the substa~ice. II'an approl~riate contl-ol g~' o i~l~ is not included. then it is not possihle to ascertain \vIiether clianges in the endpoilit ol'interest \yere due to the substance or due to ~~nrelatcd and uncontrolled cstranco~ls It'tlic baseline \.ali~cs for tlie endpoint being ~ne;~surcd arc signiticantly different. then it is difficult to intcl-pi-ct tlie findings ot'tlie i~~tcr\,ention. For example. in a sti~cly of tlie ei'lkcts of21 lo\~:-sodil~m diet on the ~i s l i 01' ca~~dio\!;~scul:~r disease. lia\:ing baseline blood 171-cssure levels liiylicr in tlie intcl-vention groi117 tli:rn in the control group ~vould lead to i~liccrtainty as to ~~~l i e t l i e r an!. obses\.ed cl'fcct resulted from tlie difference in tlie sodium intalic bct\~.ee~i tlie two ~I . C ) L I I~S .
I n tervrn tioli Studies
Contains Nonbinding Recommendations
? I l'ro\,idi~ig a '.lead-in""' diet 01-a ..\\asIi-oi~t.' perio~i-li,r studies \\.it11 21 cross-over clesign li,r a n :~dequatc duration prior to randomization can help redi~cc tlie lilielihood of tli l'l'crent bascl ine values. Statislic:~l analysis o f tlie study data is a critical tiletor becai~se it pro~!idcs tlic comparison hct\\ccn sul!jects consulning tlie substance and those not consuming tlie substance. to tlctcrmine \vhetlier there is a reduction in risk of tlie disease. I-urt1ie1-rno1.c. \\,lie11 co~idi~cting statistical analyses among more than t\vn groups. the data should be analyzed hy a test designed for mi~ltiple comparisons (e.g.. Do~if'erroni. Ili~ncan). I'lii~s \v-lien statistical analyses arc not performed between the control and intervention gl-oi~p or arc colidi~ctcd inappropriately scientific concl~~sions cannot hc drawn a b o~~t the role ol'tlic 20 A diet tliat is provided to all study groups ~pr-ior to randomizatio~i. 21 I'ime 1~1 . i o c l \\,illii~i a c1.os5-over design s t~~d q during \~!liicli sul?jccts d o tiot receive an i~ltc'r-ve~itio~i
Draft---Not for lmplementat~on si1[7stancc in reducing tlie risli c7l'the cliscasc and. therefore. the agency clocs not intend to i~s c sucl~ studies to e\.ali~atc the suhstanccldisense relatinnsliip. AS eli~ci~ssed a[70\.~. when tlie stud!. docs nor 111eusurc disease incidence or associated mortalit!. then surrogate endpoints arc essential ti)r measuring risk. Scientitic conclusions cannot be dm\&-n about tlic relationship bct\fccn the substance and risk ot'tlie disease ii'tllc risli biomarl.tcr is not a surrogate endpoint (scc cliscussion above in Section 1Il.C'). .I'he agcnc!. does not intend to LISC such studics fiwm \ \ hich scientific concli~sions cannot be dra\vn in its e\.aluation ol'lhc si~bst~~~lceldiscasc rclationsliil~.
/ -l o l l ' / o~i~y I I ,~I . S 1/1o ,s11/4\. ~~~/ I L /~I C I~~/ : ) Sti~clics that use a surrogatc enelpoint slioi~ld he concli~ctcd long enougli to ensure that any change in tlie endpoint is in reslx>nsc to the clictar!. inter\!ention. ll'tlie stildy is riln ti>r a sliol-t time period sucli that tlic elTects oftlic suhstnnce cannot be e\xluated. then scientific conclusions cannot be dra~vn aboi~t tlie ~.clationship between tlie s~~bstance and the clisease ancl. therefore. the agent!, does not intend to use such a stud!, to e\'aluatc the substanceldisease relationsliip. inter\.cntion in\ olves dietar!, advice rather than : I prescribecl diet acilninistered ilndcr a controlled condition. there should be some type of assesslnent of'tlic cli~~ngcs in intalic 01' tllc substance (e.g.. dietory asscss~iie~it 01' measurement ot'a biological sample in r c s p o~~s e to dietar! ad\rice). Willlout some tj717e of assessment of'\vlietlicr tlic clictal.!. advicc I-csultecl ill a change in intalie ot'the substance. scientific conclusions cannot be clra~vn i~h o i~t the suhstanceldiscase relationship and. tIiereti)l-e. the agency does not intend to use sri~clies that Iacli sucli an assessment to e\~aluate tlie substancclcliscasc relalionship. 11 'li(~1.0 II,L~I.L) I/IO .v/~~die.s c , o n d l l c / c d ? It is important that the study ~x>pi~Iation is rele\.ant lo the general U.S. population or the population siibgl.nup idcntificd in tlic proposed claim. '1'11~1s. FDA e\.aIuatcs each study to determine if the stud!. popi~lation lives in a n area \vIiere malni~trition or inadequate intakes of the specilic substance is cornmoll. and/or \f;liere tlie prevalence o r e t i o l o g~~ of the disease that is the sub.iect ol'tllc claim is not similar to that in tlie linited States. For certain countries. there may he risk Ii~ctors ol' ;I speciiic disease that are not relevant to clisease risk in tlic I:nited States (e.2.. risk lirctors for gastric cancer in certain Asian countries). L)ifferences in nutrition. dict. anci clisease 1.isl.c t'lrctors between tlie linited States and the country where a stucl!. was donc ma!. mcirn that tlie stud!. results cannot he extrapolated to tlic I!.S popillation or ~x)pi~lation si11~~1.0~117. For exa~iiple, scientific conclusions about tlic comparnti\'el! \yell-11oi1l.ished Ij.S. 17opi1Ii1tion cannot be drawn from studies in su1,iccts tli~rt arc ~iialnoi~rislied. Ni~trient status nnd metabolism can be sef~el-el!. altered \the11 an indi\,idi~al is ~n~~lnoi~rislied and tliercti)rc the effect ot'the substance on a pal-ticular surrogatc
Draft---Not for Implementation cllcll'oint ma! bc \,cry different hetneen a malnour~slied and well-noi~rished ~n d i \ idual (Shils et al.. 2006) . Sciclitific coricli~sions cannot be drawn from studies conclucted in countries or regions \\,liere inadecluate intalte of tlie substance is common since : I response to tlic intalic ol'tlie substance may be due to tlie correction ol'a ~iiitrie~it deticielic~. ti>r \\:IiicIi Iicalth claims not intended. I~i~rtliermore. concli~sions cannot be drawn from stndies conducted ill countries or regions \vIiel.e the etiology oftlic disease is very dil'fcrent tIia11 in the I Initctl States. I.'or example. major risk thctors for gastric ca~icer in Sapan (high salt intalie and I lelicobacter pylo~.i ( [ 1. pylori) ilifection) are signilicantly more prevalent than in tllc I lnited States. 'l'liereii~rc. it is not ap1vopri;ttc to extrapolate fi-om data o n a .lapnncsc ~x)l'i~latio~i co~~cel-ning the relationship bet~vcen a substancc and gastric cancer to reach conclusions ;tl?o~~t ~mte~itial el'lkcts o n [lie I i.S. 17opi1l:ttion. should be eviclencc to demonstrate a strong co~.relation--bet\vce~i the intake level of'tlie substance and tlie level of tlic s~tbstance or a metabolite in the biological sample (e.g.. sclcnium intalic and nail selenium concentration). II'tlie correlation is weal< fbr a slxxilic 1liologic:ll samplc. then scientific conclusions cannot be dra~vn from studies that i~sed that biologic;tl s a~n p l c as n biomarltcr of intaltc. Biological san~ples in case-control stildies slioulcl not he ilsed to establisl~ intaltc ol'the suhstancc since tlie metabolism or concentration ol'tlie substance may be altered in sul!iects \?;it11 the cliseasc (cases). \~lrcli.c~ .sc~ic~/i/ 1ficl111~ ~I L~c L~/ I~~I /~/~ l117l./ l*l~/idll/ec/ l./ie/l/i;~. ~1,v,sc>.v,v111~~17/ I I I~/ /~~~/ , Y //.sc>l/ to O . Y /~I I~~I /~~ ii7/l/k~) ( ? f ' / /~e . Y I I / I . Y / C I I~L .~:~ A single 24-hour recall is generally rcga~.ded as a n in;~clccluate method fi)r asscssil~g an indi\~idual's ~~s u a l intalic of'a substance. altlio~~yli i t ma! be uscfill for :lssessing mean intalte of a groi~p. '4 diet liistory in\,olves extensive interviews \\it11 the stud!. sul!jects. A food li-ccluency clltestionnaire contains a limited 1111117 1x1o t' thod items and is inadeclilate f'or assessing intalic ol'a specific 1i)od i I' the n)>~iol S O L I~C C S ol'tlie food arc not included in t l~c cl~~estionnai~-e. I-'ood fi-ecli~e~ic! c~i~e s t i o~~l~a i r e s also clo not al\va!.s account f'or dif'ferent varieties ol';t ~'articulal-1i)ocl 01. dil'fcrent cooking methods. Because of these limitations. \.alidation oi'thc li)od li-eclilenc!~ cluestionnairc 11iethod to assess lbod intake is essential in order to be able to cl~.a~\, c o~~c l u s i o n s tiurn the scientific data. as tlie litilu~.e to \.alidatc ma! lead to l'ltlsc 
Draft---Not for Implementation In l'nct. e\!idence demonstrates tliat in a ~ii~rnber oI'instt111cc.s. ohser\iational studies based 0 1 1 tlic recorded dietary intake of con\.el~tional fi,ods ma), indicate a benelit li)r a ~x~l.ticular ni~trient with respect to a disease but it is subsecluentl!. clcmonstrated in a11 interlwtion study tliat the nutrient-contai~ii~ig clictar!; supplement docs not confcr a 
Draft---N o t for I m p l e m e n t a t i o n com13arcd to \vl~en i t is consi~med among man!, orller ibod components. I:urthermorc. these sti~dies demonstrate tlie potential public llealtli risk of relying on results from cl>idcmiological studies. in which the ell'ect ol'a nutrient is hnscd on I-ecordcd dietary intake ol'con\:entionaI liwds as tlic sole source lbr concluding that a relationsliil-, exists I?ct\\ccn a specific nutrient and disease sisl;; the cl'l'ect could act~lall!. he liarmt'ill. For 1Ile aho\.c rcasolls. scientific conclusions ti-om observational studies cannot be clra\\m a b o i~~ a I-clationsliip bct\veen a food component and a disease. Obscr\iationaI studics. ho\\,ever.
' 4 can he used to measure associatioris bet\veen a 1 1 hole food and a disease.-I :. .\ssessing the Methodological Quality ],'or the studies tliat are not cliniinated during thc earlier evaluation. 1;DA intcnds to ~ndcl~cndcntl\ rate each such study for mctliodologicd clualit>. Studies can rccci\ e ;I Iligh. modcratc. or low cli~ality rati~ig. 1:DA intends to base this cli~ality rating on sc\,cral I:lctors related to study design. data collection. [lie clualit! of tllc statistical anal! sis. the ~!~p c ol'oi~tcome measured. ancl stud!. 13opulation characteristics olher l.llan I-clc\,ancc to 1l1c I !.S. ~x)l~rlation (e.g.. selection hias and thc pro\.;ision ol'important sul?jcct inli,rmatio~~ 1e.g.. age. smol.cc~-sl). Ii'tlle scie~~tific st11dy adecluately addressed all 01-mosl ol'tllc aho\'e f;~ctors. I:L)A plans to give it a high methodological clualit!-raring. I.'I)A plans to gi\:e moilerate or low cluality ratings hascd on the extent of tlie deficiencies 01 ilncc~.tainties in tlie clnalit!. I'actors. Studies that are so delicient in quality that the! I-ccci\!e a low cli~ality rating are studies from n~hicli scientitic conclilsions cannot hc ~II.:I\YII ahout the sul~stancc/disi.ase relatio~lsliip and asc eIimi~i:~ted for fi~rthcr rc\!ic\c.. n o informalion ti-0111 \vliicli scielititic conclusions ma! be t l r ; i \ \~i 101. llre t i l~t r i e n t itsell.. 1:11rtlicr. eveti if tlic ~i u t r i e n t s art. c o~i s~~~i i r d ill otlier foods ratlicr Illan ill a tlictal-> \~~l~l > l e r n e n~. the pIiysiolvyic;rl ct'fccts Iiiay he ditl'cre~it because the f o o d ~i i a t r i s call ;rt.fcct 11ic I~i o a \ ; r i l a h i l i t y alid h i o a c~i \ it) ot'tlie i~u t r i c l i t s . It/.
